Accéder au contenu
Merck

The Alazami Syndrome-Associated Protein LARP7 Guides U6 Small Nuclear RNA Modification and Contributes to Splicing Robustness.

Molecular cell (2020-02-06)
Daniele Hasler, Rajyalakshmi Meduri, Maciej Bąk, Gerhard Lehmann, Leonhard Heizinger, Xin Wang, Zhi-Tong Li, François M Sement, Astrid Bruckmann, Anne-Catherine Dock-Bregeon, Rainer Merkl, Reinhard Kalb, Eva Grauer, Erdmute Kunstmann, Mihaela Zavolan, Mo-Fang Liu, Utz Fischer, Gunter Meister
RÉSUMÉ

The La-related protein 7 (LARP7) forms a complex with the nuclear 7SK RNA to regulate RNA polymerase II transcription. It has been implicated in cancer and the Alazami syndrome, a severe developmental disorder. Here, we report a so far unknown role of this protein in RNA modification. We show that LARP7 physically connects the spliceosomal U6 small nuclear RNA (snRNA) with a distinct subset of box C/D small nucleolar RNAs (snoRNAs) guiding U6 2'-O-methylation. Consistently, these modifications are severely compromised in the absence of LARP7. Although general splicing remains largely unaffected, transcriptome-wide analysis revealed perturbations in alternative splicing in LARP7-depleted cells. Importantly, we identified defects in 2'-O-methylation of the U6 snRNA in Alazami syndrome siblings carrying a LARP7 mutation. Our data identify LARP7 as a bridging factor for snoRNA-guided modification of the U6 snRNA and suggest that alterations in splicing fidelity contribute to the etiology of the Alazami syndrome.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Millipore
Gel d'affinité ANTI-FLAG® M2, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
1-Methylimidazole, ReagentPlus®, 99%
Sigma-Aldrich
Anticorps anti-sous-unité B1 de l'ARN polymérase II (CTD phosphorylé sur Ser2), clone 3E10, clone 3E10, from rat